Revefenacin

Class: Antimuscarinics/Antispasmodics
VA Class: RE105
Chemical Name: 1-(2-{4-[(4-carbamoylpiperidin-1-yl)methyl]-N-methylbenzamido}ethyl) piperidin-4-yl –({1,1’-biphenyl}-2-yl) carbamate
Molecular Formula: C₃₅H₄₃N₅O₄
CAS Number: 864750-70-9
Brands: Yupelri

Medically reviewed by Drugs.com on Nov 2, 2020. Written by ASHP.

Introduction

Bronchodilator; a synthetic tertiary amine long-acting antimuscarinic agent.

Uses for Revefenacin

COPD

Long-term maintenance treatment of reversible bronchospasm associated with COPD, including chronic bronchitis and emphysema.

Not indicated for treatment of acute episodes of bronchospasm (i.e., as rescue therapy) or acute exacerbations of COPD.

Revefenacin Dosage and Administration

Administration

Administer by oral inhalation via nebulization only using a standard jet nebulizer (with mouthpiece) connected to an air compressor.

Oral Inhalation

Administer once daily at the same time every day.

Store single-dose vials of revefenacin oral inhalation solution in the foil pouch provided; remove immediately before use.

For specific information on administration of the oral inhalation solution via nebulization, consult the manufacturer’s instructions for use.

In clinical trials, a Pari LC Sprint nebulizer with a Pari Trek S compressor was used to deliver revefenacin oral inhalation solution. Safety and efficacy of the drug delivered from a nebulizer system without a compressor not established.

Do not mix with other inhalation solutions. Do not administer inhalation solution orally or by injection.

Dosage

Each 3-mL single-dose vial of revefenacin oral inhalation solution contains 175 mcg of revefenacin.

Dilution not required prior to administration by nebulization.

Amount of drug delivered to the lungs depends on patient factors, type of nebulization system used, and compressor performance.

Adults

COPD

Oral Inhalation

175 mcg (entire contents of 1 single-dose vial) once daily via nebulization.

Prescribing Limits

Adults

COPD

Oral Inhalation

Maximum 175 mcg daily.

Special Populations

Hepatic Impairment

Not recommended in patients with hepatic impairment. (See Hepatic Impairment under Cautions.)

Renal Impairment

No dosage adjustment required. (See Renal Impairment under Cautions.)

Geriatric Patients

No dosage adjustment required. (See Geriatric Use under Cautions.)